Samantha L Vogt1,2,3, Lucia Maloma3, Rena R Xian2,4, Richard F Ambinder1,2,4, Vinitha Philip5, Moosa Patel5, Neil A Martinson1,3, Tanvier Omar6. 1. Department of Medicine. 2. Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, MD, USA. 3. Perinatal HIV Research Unit (PHRU), University of the Witwatersrand, Johannesburg, South Africa. 4. Department of Pathology, Johns Hopkins School of Medicine, Baltimore, MD. 5. Clinical Haematology Unit, Department of Medicine, Chris Hani Baragwanath Academic Hospital and Faculty of Health Sciences. 6. Division of Anatomical Pathology, National Health Laboratory Service, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Abstract
OBJECTIVE: Fine needle aspiration (FNA) is an early step in the work-up of lymphadenopathy in people with HIV (PWH). We set out to characterize the FNA cytology in PWH and report on the time to lymphoma diagnosis through the FNA clinics in the public healthcare system in Johannesburg, South Africa. DESIGN: Retrospective review of laboratory database. METHODS: A retrospective chart review of patients undergoing FNA through the department of cytopathology at the National Health Laboratory Service (NHLS) was undertaken. Results of FNAs performed between March and May 2018 were reviewed. Medical record chart abstraction included general demographics, HIV status, site and results of FNA, prior history of malignancy and other laboratory data. RESULTS: Five hundred and thirty-nine lymph node FNAs were performed on PWH. Pathological findings included tuberculosis 47% (252), inadequate sampling 14% (75), reactive adenopathy 13% (71), benign disease 12% (63), suspicious for lymphoproliferative neoplasm 8% (45), other malignancy 4% (21) and inflammation 2% ( n = 12). Only 53% (24) of lymphomas were confirmed by biopsy. Those not confirmed had a high mortality (57%) and loss to follow-up rate (29%) over the following year. The median diagnostic interval exceeded 8 weeks from time of FNA to lymphoma diagnosis. CONCLUSION: FNA is an important screening modality in this high HIV and tuberculosis (TB) burden region. Patients with cytology suggestive for lymphoma, but without biopsy confirmation, have a high mortality rate suggesting undiagnosed lymphoma. A better understanding of the barriers to appropriate diagnostic triage for lymphoma is needed.
OBJECTIVE: Fine needle aspiration (FNA) is an early step in the work-up of lymphadenopathy in people with HIV (PWH). We set out to characterize the FNA cytology in PWH and report on the time to lymphoma diagnosis through the FNA clinics in the public healthcare system in Johannesburg, South Africa. DESIGN: Retrospective review of laboratory database. METHODS: A retrospective chart review of patients undergoing FNA through the department of cytopathology at the National Health Laboratory Service (NHLS) was undertaken. Results of FNAs performed between March and May 2018 were reviewed. Medical record chart abstraction included general demographics, HIV status, site and results of FNA, prior history of malignancy and other laboratory data. RESULTS: Five hundred and thirty-nine lymph node FNAs were performed on PWH. Pathological findings included tuberculosis 47% (252), inadequate sampling 14% (75), reactive adenopathy 13% (71), benign disease 12% (63), suspicious for lymphoproliferative neoplasm 8% (45), other malignancy 4% (21) and inflammation 2% ( n = 12). Only 53% (24) of lymphomas were confirmed by biopsy. Those not confirmed had a high mortality (57%) and loss to follow-up rate (29%) over the following year. The median diagnostic interval exceeded 8 weeks from time of FNA to lymphoma diagnosis. CONCLUSION: FNA is an important screening modality in this high HIV and tuberculosis (TB) burden region. Patients with cytology suggestive for lymphoma, but without biopsy confirmation, have a high mortality rate suggesting undiagnosed lymphoma. A better understanding of the barriers to appropriate diagnostic triage for lymphoma is needed.
Authors: Stefan K Barta; Xiaonan Xue; Dan Wang; Jeannette Y Lee; Lawrence D Kaplan; Josep-Maria Ribera; Albert Oriol; Michele Spina; Umberto Tirelli; Francois Boue; Wyndham H Wilson; Christoph Wyen; Kieron Dunleavy; Ariela Noy; Joseph A Sparano Journal: Haematologica Date: 2014-08-22 Impact factor: 9.941
Authors: Michael J Silverberg; Bryan Lau; Chad J Achenbach; Yuezhou Jing; Keri N Althoff; Gypsyamber D'Souza; Eric A Engels; Nancy A Hessol; John T Brooks; Ann N Burchell; M John Gill; James J Goedert; Robert Hogg; Michael A Horberg; Gregory D Kirk; Mari M Kitahata; Philip T Korthuis; William C Mathews; Angel Mayor; Sharada P Modur; Sonia Napravnik; Richard M Novak; Pragna Patel; Anita R Rachlis; Timothy R Sterling; James H Willig; Amy C Justice; Richard D Moore; Robert Dubrow Journal: Ann Intern Med Date: 2015-10-06 Impact factor: 25.391
Authors: E A Abayomi; A Somers; R Grewal; G Sissolak; F Bassa; D Maartens; P Jacobs; C Stefan; L W Ayers Journal: Transfus Apher Sci Date: 2011-04 Impact factor: 1.764
Authors: Nikolaus C S Mezger; Jana Feuchtner; Mirko Griesel; Lucia Hämmerl; Tobias P Seraphin; Annelle Zietsman; Jean-Félix Péko; Fisihatsion Tadesse; Nathan G Buziba; Henry Wabinga; Mary Nyanchama; Margaret Z Borok; Mamadou Kéita; Guy N'da; Cesaltina F Lorenzoni; Marie-Thérèse Akele-Akpo; Cornelia Gottschick; Mascha Binder; Jörg Mezger; Ahmedin Jemal; Donald M Parkin; Claudia Wickenhauser; Eva J Kantelhardt Journal: Br J Haematol Date: 2020-03-17 Impact factor: 6.998
Authors: Shiraz Khan; George Liomba; Nora E Rosenberg; Christopher Stanley; Cocxilly Kampani; Bal Mukunda Dhungel; Mina C Hosseinipour Journal: PLoS One Date: 2018-06-12 Impact factor: 3.240
Authors: Michael G Milligan; Elizabeth Bigger; Jeremy S Abramson; Aliyah R Sohani; Musimar Zola; Mukendi K A Kayembe; Heluf Medhin; Gita Suneja; Shahin Lockman; Bruce A Chabner; Scott L Dryden-Peterson Journal: J Glob Oncol Date: 2018-09